Aspen Offers To Slash Prices On Cancer Drugs In EU Probe
Aspen Pharmacare Holdings Ltd. has offered to lower the prices of six cancer medications sold in the European Union by over 70%, in order to address the EU competition authority's concerns...To view the full article, register now.
Already a subscriber? Click here to view full article